Edition:
United States

Sarepta Therapeutics Inc (SRPT.OQ)

SRPT.OQ on NASDAQ Stock Exchange Global Select Market

54.26USD
11 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$54.26
Open
--
Day's High
--
Day's Low
--
Volume
202
Avg. Vol
577,628
52-wk High
$57.50
52-wk Low
$26.26

Latest Key Developments (Source: Significant Developments)

Sarepta Therapeutics prices $475 million of convertible senior notes due 2024
Wednesday, 8 Nov 2017 07:14pm EST 

Nov 8 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics prices $475 million of convertible senior notes due 2024.Sarepta Therapeutics-‍priced $475 million aggregate principal amount of convertible senior unsecured notes that will mature on November 15, 2024​.Sarepta Therapeutics - ‍notes will bear cash interest at a rate of 1.50%, payable on May 15 and November 15 of each year, beginning on May 15, 2018​.  Full Article

Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes
Tuesday, 7 Nov 2017 04:15pm EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces proposed offering of $375 million of convertible senior notes due 2024.Sarepta Therapeutics Inc - ‍Chief Executive Officer indicates interest in purchasing $2 million of shares of Sarepta's common stock​.Sarepta - ‍intends to use a portion of net proceeds from offering to pay cost of certain capped call transactions​.Sarepta - ‍purchase price/share of stock bought by ingram expected to equal closing price/share of co's stock on date of pricing of offering​.  Full Article

Sarepta Therapeutics reports FDA clearance of IND for co's ppmo exon 51 candidate, srp-5051
Tuesday, 7 Nov 2017 08:30am EST 

Nov 7 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces FDA clearance of IND for the company's ppmo exon 51 candidate, srp-5051.Sarepta Therapeutics Inc - will immediately initiate its phase 1/2a clinical trial and begin screening patients with dmd amenable to skipping exon 51​.  Full Article

Sarepta Therapeutics says FDA clears gene therapy IND application
Friday, 3 Nov 2017 08:30am EDT 

Nov 3 (Reuters) - Sarepta Therapeutics Inc -:Sarepta Therapeutics and Nationwide Children’S Hospital announce U.S. Food And Drug Administration (FDA) clearance of the IND application for the GALGT2 gene therapy program.Sarepta Therapeutics- ‍IND application for GALGT2 gene therapy program was cleared by FDA​.Sarepta Therapeutics - Nationwide Children's is on track to initiate Phase 1/2A clinical trial in individuals with DMD by year-end 2017 ​.  Full Article

Sarepta Therapeutics signs exclusive global collaboration with Duke University
Tuesday, 31 Oct 2017 08:30am EDT 

Oct 31 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics signs exclusive global collaboration with Duke University for Gene Editing CRISPR/CAS9 technology to develop new treatments for Duchenne Muscular Dystrophy (DMD).Sarepta Therapeutics Inc - ‍financial terms of agreement have not been disclosed​.  Full Article

Sarepta Therapeutics sees FY17 revenue $150 mln to $155 mln
Wednesday, 25 Oct 2017 04:01pm EDT 

Oct 25 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces third quarter 2017 financial results and recent corporate developments.Q3 non-GAAP loss per share $0.20.Q3 earnings per share view $-0.85 -- Thomson Reuters I/B/E/S.Q3 GAAP loss per share $0.78.Sees FY 2017 revenue $150 million to $155 million.Q3 revenue $46 million versus I/B/E/S view $40.8 million.Sarepta Therapeutics Inc - ‍raises annual 2017 revenue guidance to between $150 million and $155 million​.  Full Article

Sarepta Therapeutics reports positive results in study
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces positive results in its study evaluating gene expression, dystrophin production, and dystrophin localization in patients with duchenne muscular dystrophy (DMD) amenable to skipping exon 53 treated with golodirsen (SRP-4053).Sarepta Therapeutics Inc - ‍study achieved statistical significance on all primary and secondary biological endpoints​.Sarepta Therapeutics Inc - ‍study also showed a statistically significant increase in dystrophin immunofluorescence as measured by immunohistochemistry​.  Full Article

Sarepta Therapeutics announces pricing of $325 mln public offering of common stock
Monday, 24 Jul 2017 08:03pm EDT 

July 24 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces pricing of $325 million public offering of common stock.Sarepta Therapeutics - Priced underwritten public offering of an aggregate of 7.65 million shares of common stock at a price to public of $42.50 per share.  Full Article

Sarepta Therapeutics announces proposed $250 mln public offering of common stock
Monday, 24 Jul 2017 07:00am EDT 

July 24 (Reuters) - Sarepta Therapeutics Inc ::Sarepta Therapeutics announces proposed $250 million public offering of common stock.Sarepta - intends to use net proceeds from offering principally for continuation and initiation of further clinical trials.  Full Article

Sarepta Therapeutics announces Q2 revenue $35 million
Wednesday, 19 Jul 2017 04:01pm EDT 

July 19 (Reuters) - Sarepta Therapeutics Inc :Sarepta Therapeutics announces second quarter 2017 financial results and recent corporate developments.Q2 non-GAAP loss per share $0.46.Q2 revenue $35 million.Q2 revenue view $22.4 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view $-0.91 -- Thomson Reuters I/B/E/S.Q2 GAAP loss per share $1.15.Sarepta Therapeutics Inc says increased revenue guidance range to $125 - $130 million for year.  Full Article

Sarepta Therapeutics investors seek revival of fraud lawsuit

A lawyer for Sarepta Therapeutics Inc shareholders urged a federal appeals court on Monday to revive a lawsuit claiming the company misled investors about whether it had gathered enough data to seek Food and Drug Administration approval for a treatment for a rare muscle disorder.